These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35535145)

  • 1. CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma.
    Liu L; Hui R; Zeng T; Yang X; Wu Q; Yang T
    Int J Gen Med; 2022; 15():4613-4623. PubMed ID: 35535145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
    [No Abstract]   [Full Text] [Related]  

  • 4. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
    Lin P; Zhao Y; Li X; Liang Z
    Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
    Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
    Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
    Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
    Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
    Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.
    Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K
    Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
    Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
    Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
    Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS
    Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
    Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ
    Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
    Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD
    Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines.
    Kuramitsu Y; Miyamoto H; Tanaka T; Zhang X; Fujimoto M; Ueda K; Tanaka T; Hamano K; Nakamura K
    Proteomics; 2009 Nov; 9(22):5078-89. PubMed ID: 19771552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.